Learn how an integrated High-Throughput workflow compresses antibody development timelines to rapidly identify and validate ADCC-enhanced lead candidates.
Summary
This poster focuses on evitria’s High-Throughput antibody expression pipeline from candidate selection and scale-up of ADCC-enhanced variants to mechanistic characterization by our partner
Biofidus. Leveraging robust, standardized processes with high flexibility, evitria offers expertise in
bispecific development, High-Throughput expression, and Fc-engineered antibodies. We also inlicence technologies such as ProBioGen’s GlymaxX system, which afucosylates the antibody Fc to enhance ADCC effector function.
Download the poster to see the full workflow.
